spacer
home > ebr > spring 2018 > precision healthcare
PUBLICATIONS
European Biopharmaceutical Review

Precision Healthcare

At the end of January, industry observers were brimming with speculation on the likely course of Amazon’s entry into healthcare. Championed by a corporation known for ‘disruptive innovation’ in the technology and retail sectors, this project promises to challenge the status quo in the world’s largest healthcare system that is characterised by a fragmented market, entrenched providers, dysfunctional incentives, and little consumer choice.

The manifesto of this bold project by Amazon, JP Morgan, and Berkshire- Hathaway is both challenging and modest: “Our goal is to benefit [1.2 million] US employees and their families, and potentially all Americans.” In short, the goal is to remake the market for healthcare so it becomes integrated, transparent, equitable, and more affordable. Success would not be measured by immediate financial returns, but by long-term impact. Many analysts saw the venture as the opening gambit in online retail pharmacy. This has been the buzz since Amazon acquired Whole Foods Markets last year. Consumers will derive benefit from the online utility of Amazon, as Alibaba is already proving in China.

Amazon fields best-in-class e-commerce, distribution, fulfilment, and technology. In the industry press, the mantra was ‘bricks and clicks’, but in classic economic theory, such an enterprise could upend the supply chain by disintermediation, while using its purchasing power to lower costs to consumers and achieving dominance by sheer scale and reach. Consumer costs would certainly decrease by leveraging the existing customer base and Amazon skill sets.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, a China watcher, and an industry consultant with experience in the biotechnology and biopharmaceutical industries.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

EU GDP Guidelines: Implications for Shipping Clinical Materials into the European Market

PCI Pharma Services

Recently, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mold on paracetamol (acetaminophen) tablets (1). It discovered the product was shipped by sea from India to multiple companies in the UK at temperatures reaching up to 60 degrees Celsius. Labeling for paracetamol tablets typically states they should be kept below 30 degrees Celsius. In addition, MHRA discovered the humidity levels exceeded 80 percent during shipping, which is too high for the packaging that was used.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement